Literature DB >> 17017543

Alpha-synuclein overexpression model.

H Mochizuki1, M Yamada, Y Mizuno.   

Abstract

OBJECTIVES: To elucidate the role of alpha-synuclein in the pathogenesis of Parkinson's disease (PD), both human alpha-synuclein transgenic mice and targeted overexpression of human alpha-synuclein in rat substantia nigra (SN) by viral vector-based methods have been studied, however little is known about the pathogenetic changes of dopaminergic neuron loss. Therefore, it is necessary to address whether the pathogenetic changes in the brains of patients with PD are recapitulated in these models. METHODS AND
RESULTS: We used the recombinant adeno-associated viral (rAAV) vector system for human alpha-synuclein gene transfer to rat SN and observed approximately 50% loss of dopaminergic neurons in SN at 13 weeks after infection. In the slower progression of neurodegeneration, we identified several important features in common with the pathogenesis of PD, such as phosphorylation of alpha-synuclein at Ser129 and activation of caspase-9. Both findings were also evident in cortical tissues overexpressing alpha-synuclein via rAAV.
CONCLUSIONS: Our results indicate that overexpression of alpha-synuclein via rAAV apparently recapitulates several important features of brains with PD and dementia with Lewy bodies (DLB), and thus alpha-synucleinopathy described here is likely to be an ideal model for the study of the pathogenesis of PD and DLB. This model is also useful for the gene therapy research.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17017543

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  11 in total

1.  Persistent EcoHIV infection induces nigral degeneration in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-intoxicated mice.

Authors:  Katherine E Olson; Aditya N Bade; Krista L Namminga; Mary Jane Potash; R Lee Mosley; Larisa Y Poluektova; David J Volsky; Howard E Gendelman
Journal:  J Neurovirol       Date:  2018-03-28       Impact factor: 2.643

2.  Strategies to gain novel Alzheimer's disease diagnostics and therapeutics using modulators of ABCA transporters.

Authors:  Jens Pahnke; Pablo Bascuñana; Mirjam Brackhan; Katja Stefan; Vigneshwaran Namasivayam; Radosveta Koldamova; Jingyun Wu; Luisa Möhle; Sven Marcel Stefan
Journal:  Free Neuropathol       Date:  2021-12-13

3.  Dominant-positive HSF1 decreases alpha-synuclein level and alpha-synuclein-induced toxicity.

Authors:  Xu Liangliang; Hou Yonghui; E Shunmei; Gong Shoufang; Zhou Wei; Zou Jiangying
Journal:  Mol Biol Rep       Date:  2009-07-17       Impact factor: 2.316

Review 4.  In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease?

Authors:  Marie-Francoise Chesselet
Journal:  Exp Neurol       Date:  2007-08-23       Impact factor: 5.330

Review 5.  The Path to Progress Preclinical Studies of Age-Related Neurodegenerative Diseases: A Perspective on Rodent and hiPSC-Derived Models.

Authors:  Gabriella MacDougall; Logan Y Brown; Boris Kantor; Ornit Chiba-Falek
Journal:  Mol Ther       Date:  2021-01-09       Impact factor: 11.454

Review 6.  Alpha-synuclein, Proteotoxicity and Parkinson's Disease: Search for Neuroprotective Therapy.

Authors:  Upasana Ganguly; Sankha Shubhra Chakrabarti; Upinder Kaur; Anwesha Mukherjee; Sasanka Chakrabarti
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

7.  Ceftriaxone Treatment for Neuronal Deficits: A Histological and MEMRI Study in a Rat Model of Dementia with Lewy Bodies.

Authors:  Ying-Jui Ho; Jun-Cheng Weng; Chih-Li Lin; Mei-Shiuan Shen; Hsin-Hua Li; Wen-Chieh Liao; Nu-Man Tsai; Ching-Sui Hung; Te-Jen Lai; I-Yen Lee
Journal:  Behav Neurol       Date:  2018-08-01       Impact factor: 3.342

8.  Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting α-synuclein as a novel therapy for Parkinson's disease.

Authors:  Takuya Uehara; Chi-Jing Choong; Masayuki Nakamori; Hideki Hayakawa; Kumiko Nishiyama; Yuuya Kasahara; Kousuke Baba; Tetsuya Nagata; Takanori Yokota; Hiroshi Tsuda; Satoshi Obika; Hideki Mochizuki
Journal:  Sci Rep       Date:  2019-05-21       Impact factor: 4.379

9.  Use of Ceftriaxone in Treating Cognitive and Neuronal Deficits Associated With Dementia With Lewy Bodies.

Authors:  Ying-Jui Ho; Mei-Shiuan Shen; Chun-Hwei Tai; Hsin-Hua Li; Jian-Horng Chen; Wen-Chieh Liao; Pai-Yi Chiu; I-Yen Lee; Chih-Li Lin; Ching-Sui Hung
Journal:  Front Neurosci       Date:  2019-05-24       Impact factor: 4.677

Review 10.  Neuronal cell death in neurodegenerative diseases: recurring themes around protein handling.

Authors:  Adrienne M Gorman
Journal:  J Cell Mol Med       Date:  2008-06-27       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.